New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:39 EDTARIAARIAD announces longer-term follow up from Phase 1, Phase 2 Iclusig trials
ARIAD Pharmaceuticals announced longer-term follow up from its Phase 1 and pivotal Phase 2 trials of Iclusig, its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The studies now show that with a median follow-up of 42.5 months for chronic-phase CML patients in the Phase 1 trial, Iclusig continues to demonstrate anti-leukemic activity in those who had limited treatment options, and that deep and durable responses have been maintained in CP-CML patients in the PACE trial with 87 percent estimated to remain in major cytogenetic response at two years. Longer-term safety data show that careful benefit/risk evaluation should guide the decision to use ponatinib therapy, particularly in patients who may be at increased risk for vascular occlusive events.
News For ARIA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 22, 2015
07:37 EDTARIAARIAD announces data presentations at EHA Congress
Subscribe for More Information
May 20, 2015
10:29 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: ZIOP KING ARIA CTRP WTW VHC XON KERX VIPS JCP
May 19, 2015
11:59 EDTARIAOptions with decreasing implied volatilit
Subscribe for More Information
May 18, 2015
10:37 EDTARIAOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 14, 2015
08:04 EDTARIAARIAD to present data on Iclusig, brigatinib at ASCO meeting
Subscribe for More Information
May 12, 2015
07:52 EDTARIALeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use